Westminster biotech company shares new strategy for cancer treatments.
By: Colorado BioScience Association Date: 09/29/2020
A Westminster biotech company has a new clinical development strategy following a recent acquisition it made.
TriSalus Life Sciences is an emerging immuno-oncology company that has developed technology to better administer treatments in solid tumors. But through its acquisition of SD-101, an immunotherapy developed by Dynavax Technologies, TriSalus now has the treatment to couple with its technology.
Find out more in the Denver Business Journal